Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GRI
Upturn stock ratingUpturn stock rating

GRI Bio Inc. (GRI)

Upturn stock ratingUpturn stock rating
$1.39
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: GRI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $22

1 Year Target Price $22

Analysts Price Target For last 52 week
$22 Target price
52w Low $1.1
Current$1.39
52w High $30.43

Analysis of Past Performance

Type Stock
Historic Profit -70.74%
Avg. Invested days 38
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.50M USD
Price to earnings Ratio 0.02
1Y Target Price 22
Price to earnings Ratio 0.02
1Y Target Price 22
Volume (30-day avg) 2
Beta -1.83
52 Weeks Range 1.10 - 30.43
Updated Date 08/29/2025
52 Weeks Range 1.10 - 30.43
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 90.8

Earnings Date

Report Date 2025-08-14
When Before Market
Estimate -1.31
Actual -1.31

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -98.68%
Return on Equity (TTM) -248.92%

Valuation

Trailing PE 0.02
Forward PE -
Enterprise Value -1529727
Price to Sales(TTM) -
Enterprise Value -1529727
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 2515300
Shares Floating 2514701
Shares Outstanding 2515300
Shares Floating 2514701
Percent Insiders 0.02
Percent Institutions 0.78

ai summary icon Upturn AI SWOT

GRI Bio Inc.

stock logo

Company Overview

overview logo History and Background

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory, fibrotic, and autoimmune diseases. Founded in 2020, GRI Bio is leveraging its Tissue-Targeted Therapeuticsu2122 (TTT) platform to discover and develop targeted therapies that can selectively modulate the immune system at the site of disease. GRI Bio merged with Vallon Pharmaceuticals, Inc. in 2023.

business area logo Core Business Areas

  • GVIN Module Program: Lead program targeting innate immune checkpoint VISTA (V-domain Ig suppressor of T cell activation) for treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.
  • Platform Technology: Tissue-Targeted Therapeuticsu2122 (TTT) platform to discover and develop targeted therapies that can selectively modulate the immune system at the site of disease.

leadership logo Leadership and Structure

The leadership team includes CEO Dr. Bedi, as well as other executives with expertise in drug development and commercialization. The company has a board of directors overseeing its strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • GVIN Module: Lead program targeting VISTA. Currently in clinical development for IPF. Market share is not yet applicable as the product is pre-revenue. Competitors in IPF include Boehringer Ingelheim (OFEV and Vargatramestan) and Roche (Esbriet).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and rapidly evolving, with significant investment in research and development. The market for inflammatory and fibrotic disease therapies is substantial and growing.

Positioning

GRI Bio is positioned as a company with a novel approach to treating inflammatory and fibrotic diseases, utilizing its TTT platform to develop targeted therapies. Its competitive advantage lies in its potential to develop more effective and safer treatments compared to existing therapies.

Total Addressable Market (TAM)

The TAM for IPF alone is estimated to be multi-billion dollar and could be a good indication. GRI Bio targets larger fibrosis markets. The company focuses on innovative treatment of the disease

Upturn SWOT Analysis

Strengths

  • Novel TTT platform
  • Targeting VISTA, a promising immune checkpoint
  • Experienced management team
  • Strong IP portfolio (pending & granted)

Weaknesses

  • Early stage clinical development
  • Limited financial resources
  • Reliance on successful clinical trial outcomes
  • Dependency on key personal

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into other inflammatory and fibrotic diseases
  • Positive clinical trial results leading to regulatory approval
  • Further development of TTT platform

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • BI
  • Roche
  • Bristol Myers Squibb (BMY)

Competitive Landscape

GRI Bio competes with established pharmaceutical companies that have approved therapies for inflammatory and fibrotic diseases. GRI Bio's competitive advantage lies in its novel TTT platform and its focus on VISTA, but it faces challenges related to its early stage of development and limited resources.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited as the company is relatively new. Growth is primarily focused on advancing its clinical programs.

Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst estimates are not available at this time.

Recent Initiatives: Advancing the GVIN module into further clinical trials; expanding preclinical research efforts; searching for partnership opportunities to enhance the TTT platform and program advancement.

Summary

GRI Bio is an early-stage biopharmaceutical company with a promising platform technology for treating inflammatory and fibrotic diseases. Its focus on VISTA and targeted therapies could lead to significant breakthroughs. The company's success depends on successful clinical trials and securing partnerships to advance its programs. It needs to monitor risks to the trials and look for partnerships.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • GRI Bio Inc. corporate website
  • SEC Filings
  • Industry Reports
  • Analyst Reports (where available)

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimated and may not be precise. Financial data may be outdated. Consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About GRI Bio Inc.

Exchange NASDAQ
Headquaters La Jolla, CA, United States
IPO Launch date 2021-02-10
Co-Founder, CEO, President & Director Dr. W. Marc Hertz Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 3
Full time employees 3

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.